Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254429 | 0.83 | HTR7 (0.60) | MAPTSMN1; SMN2HTR7ALDH1A1DRD1 | |
| SCHEMBL1254641 | 0.82 | HTR7 (0.66) | HTR7DRD1DRD3 | |
| SCHEMBL1254473 | 0.82 | HTR7 (0.63) | HTR7DRD1DRD3 | |
| SCHEMBL9805060 | 0.72 | SMN1; SMN2 (0.63) | MAPTSMN1; SMN2ALDH1A1POLBLMNA | |
| SCHEMBL11279556 | 0.72 | MAPT (0.63) | MAPTSMN1; SMN2ALDH1A1POLBLMNA | |
| SCHEMBL7853505 | 0.72 | TRPV1 (0.56) | MAPTSMN1; SMN2HTR7ALDH1A1POLB | |
| SCHEMBL2196037 | 0.72 | HTR7 (0.45) | HTR7DRD1DRD3 | |
| SCHEMBL12418239 | 0.71 | KCNH2 (0.52) | MAPTSMN1; SMN2HTR7ALDH1A1DRD3 | |
| SCHEMBL11914802 | 0.70 | ALDH1A1 (0.60) | MAPTSMN1; SMN2ALDH1A1POLBLMNA | |
| SCHEMBL2191733 | 0.70 | HTR7 (0.50) | HTR7DRD1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2219648-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009062134-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-1764134-B1 | Purine derivatives linked to arylpiperazines | SPECTRUM PHARMACEUTICALS INC (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-1412028-B1 | TETRAHYDROINDOLONE DERIVATIVES LINKED TO ARYLPIPERAZINES | SPECTRUM PHARMACEUTICALS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1764134-A2 | Tetrahydroindolone and purine derivatives linked to arylpiperazines | Spectrum Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20050107439-A1 | Composition and method for treating emesis | HELTON DAVID R (US) | 2005-05-19 | — | — | US | disclosed |
| US-6770638-B2 | PSYCHOLOGICAL DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | SPECTRUM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030114463-A1 | Tetrahydroindolone and purine derivatives linked to arylpiperazines | SPECTRUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | HTR5A, HTR2C, HTR3B | MAPT 2521/4885SMN1; SMN2 4626/4885HTR7 20/4885 |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | MAPT 3987/4885SMN1; SMN2 3984/4885HTR7 199/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | MAPT 3987/4885SMN1; SMN2 3984/4885HTR7 199/4885 |
| US-20030114463-A1 | Tetrahydroindolone and purine derivatives linked to arylpiperazines | HTR5A, GABRA5, HTR2C | MAPT 1264/4885SMN1; SMN2 3063/4885HTR7 7/4885 |
| US-20050107439-A1 | Composition and method for treating emesis | VIP, HNMT, FABP2 | MAPT 3676/4885SMN1; SMN2 1233/4885HTR7 119/4885 |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | MAPT 3987/4885SMN1; SMN2 3984/4885HTR7 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.